JPH0925290A - New compound included in sugar beet, medical composition and function food - Google Patents

New compound included in sugar beet, medical composition and function food

Info

Publication number
JPH0925290A
JPH0925290A JP7177220A JP17722095A JPH0925290A JP H0925290 A JPH0925290 A JP H0925290A JP 7177220 A JP7177220 A JP 7177220A JP 17722095 A JP17722095 A JP 17722095A JP H0925290 A JPH0925290 A JP H0925290A
Authority
JP
Japan
Prior art keywords
sugar beet
extract
formula
glu
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7177220A
Other languages
Japanese (ja)
Inventor
Masayuki Yoshikawa
雅之 吉川
Shoichi Harima
章一 播磨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokiwa Kanpo Pharmaceutical Co Ltd
Original Assignee
Tokiwa Kanpo Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokiwa Kanpo Pharmaceutical Co Ltd filed Critical Tokiwa Kanpo Pharmaceutical Co Ltd
Priority to JP7177220A priority Critical patent/JPH0925290A/en
Publication of JPH0925290A publication Critical patent/JPH0925290A/en
Pending legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To obtain a new compound included in sugar beets, a sugar beet saponin obtained from an extract of sugar beets, having blood glucose-reducing activities, low toxicity and no limitation in doses and useful as a blood glucose- reducing agent, functional food, etc. SOLUTION: This new compound comprises sugar beet saponin compound expressed by formula I (R<1> is H or -D-Glu; R<3> and R<4> are each H or CH3 ) or formula II (R<2> is H or -D-Glu). The new compound has blood glucose-reducing activities, low toxicity and no limitation in doses and is useful as a blood glucose-reducing agent, functional food, etc. The compound can be obtained by adding 50% aqueous methanol to sugar beets cut in small sizes, heat- extracting under reflux for 3 hours, filtrating the extracted solution, removing methanol under reduced pressure, lyophilizing the resulting material to obtain a water-containing methanol extract which is treated with a reverse-phase silica gel column, eluted with water to remove sucrose, eluted with methanol and purified the obtained fraction by a high speed liquid chromatography, etc.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明はテンサイに含まれる
新規化合物およびこれらの化合物を含む血糖降下剤およ
び機能性食品に関する。
TECHNICAL FIELD The present invention relates to novel compounds contained in sugar beet, hypoglycemic agents and functional foods containing these compounds.

【0002】テンサイ(Beta vulgaris)はアカザ科の
植物で、ヨーロッパ原産の野生種から改良されたもの
で、本州北部、北海道などで栽培される多年草である。
高さ60〜90cmで根が肉質で紡錘形に肥大し、肉は
白黄または紅色である。根ぎわから長い柄のある長卵形
の葉が群生し、質があつい。夏、高さ1mばかりの茎を
延ばし、多数の黄緑色の小花を穂状花序に付ける。葉は
食用になる。根はしょ糖を15〜18%含み、テンサイ
糖(ビートシュガー)の原料となる。根をくだいて、し
ぼり汁に石灰を加えて煮て、浮き上がった不純物を除
き、煮詰めて白下糖を製造し、精製する。
Sugar beet ( Beta vulgaris ) is a plant of the family Rhinoceros family, improved from a wild species native to Europe, and is a perennial plant cultivated in northern Honshu, Hokkaido and the like.
At a height of 60 to 90 cm, the roots are fleshy and have a spindle-shaped enlargement, and the meat is white-yellow or crimson. From the roots, long-oval leaves with a long handle are clustered and the quality is high. In the summer, the stem, which is about 1 m high, is extended and many yellow-green florets are attached to the spikes. The leaves are edible. The root contains 15 to 18% sucrose and is a raw material for sugar beet (beet sugar). Pour roots, add lime to squeezed juice and boil to remove floating impurities, boil down to produce white sucrose, and purify.

【0003】根は漢方薬では鎮静作用および通経作用を
示すことが知られている。テンサイの化学成分として
は、サポニン、ベータシアニンおよびフェノール性化合
物の存在が知られており、最近では、この植物の葉から
数種類のオレアノール酸配糖体が確認された。
It is known that roots show sedative and menstrual action in Chinese medicine. The presence of saponins, betacyanins and phenolic compounds are known as the chemical constituents of sugar beet, and recently several kinds of oleanolic acid glycosides have been identified from the leaves of this plant.

【0004】[0004]

【課題を解決するための手段】食用植物の生物学的活性
物質の研究において、テンサイの根および葉に由来する
サポニン画分が、ラットにおける経口ブドウ糖負荷試験
における血漿ブドウ糖値の上昇を阻害する効果を示すこ
とが判明した。このたびは低血糖性サポニン成分の研究
の続きとして、テンサイの根および葉の活性成分の化学
的研究を行い、ベータブルガロシドI(1)、II
(2)、III(3)、IV(4)およびV(5)を分離、
精製した。さらに、これらの成分が血糖降下作用を示す
ことも確認された。
[Means for Solving the Problems] In studies of biologically active substances in edible plants, saponin fractions derived from roots and leaves of sugar beet inhibit the increase in plasma glucose level in an oral glucose tolerance test in rats. Was found to show. This time, as a continuation of the research on the hypoglycemic saponin component, we conducted a chemical study on the active components of the root and leaf of sugar beet to find out that beta bulgaroside I (1), II
Separating (2), III (3), IV (4) and V (5),
Purified. Furthermore, it was also confirmed that these components have a hypoglycemic effect.

【0005】本発明は、式A:The present invention provides the formula A:

【化5】 [式中、R1は、Hまたはβ−D−Gluであり、R3およ
びR4は、HまたはCH3である]で示される化合物、よ
り具体的には、ベータブルガロシドIおよびIIに代表さ
れるものであり、さらに、式B:
Embedded image [Wherein R 1 is H or β-D-Glu, and R 3 and R 4 are H or CH 3 ], more specifically beta bulgaroside I and II And is represented by the formula B:

【化6】 [式中、R1、R3およびR4は前記と同じ意味であり、
2は、Hまたはβ−D−Gluである]で示される化合
物、より具体的には、ベータブルガロシドIII、IVおよ
びVに代表される化合物である。
[Chemical 6] [Wherein R 1 , R 3 and R 4 have the same meanings as described above,
R 2 is H or β-D-Glu], more specifically compounds represented by beta bulgaroside III, IV and V.

【0006】本発明はさらに上記の化合物の少なくとも
1種を含むテンサイの抽出エキス、および上記の化合物
の少なくとも1種またはこれを含む抽出エキスを有効成
分とする血糖降下活性医薬組成物および機能性食品を提
供するものである。
The present invention further comprises an extract of sugar beet containing at least one of the above compounds, and a pharmaceutical composition for lowering blood glucose activity and functional foods containing at least one of the above compounds or an extract containing the same as an active ingredient. Is provided.

【0007】本発明は、また、式A:The present invention also provides the formula A:

【化7】 [式中、R1は、Hまたはβ−D−Gluであり、R3およ
びR4は、Hまたは低級アルキルである]で示される化
合物、および式B:
Embedded image [Wherein R 1 is H or β-D-Glu, and R 3 and R 4 are H or lower alkyl], and a compound of formula B:

【化8】 [式中、R1、R3およびR4は前記と同じ意味であり、
2は、Hまたはβ−D−Gluである]で示される化合物
の少なくとも1種を有効成分として含む血糖降下活性医
薬組成物を提供するものである。
Embedded image [Wherein R 1 , R 3 and R 4 have the same meanings as described above,
R 2 is H or β-D-Glu], which provides a hypoglycemic active pharmaceutical composition containing at least one compound represented by the formula [2] as an active ingredient.

【0008】上記において、β−D−Gluとはβ−D−グ
ルコースの略称である。また低級アルキルとは、飽和の
直鎖または分枝状の、炭素原子1〜6個、好ましくは1
〜5個、より好ましくは1〜4個を含む炭化水素残基を
いう。例えばメチル、エチル、プロピル、イソプロピ
ル、ブチル、t−ブチルなどが含まれる。
In the above, β-D-Glu is an abbreviation for β-D-glucose. Lower alkyl is a saturated straight-chain or branched chain having 1 to 6 carbon atoms, preferably 1
~ 5, more preferably 1 to 4 hydrocarbon residues. For example, methyl, ethyl, propyl, isopropyl, butyl, t-butyl and the like are included.

【0009】医薬組成物は、好ましくは経口投与される
ものであり、その形態には、散剤、顆粒剤、細粒剤、カ
プセル剤、錠剤、丸剤、液剤などが含まれる。上記の化
合物および抽出エキスがビート・シュガーの成分であ
り、食品の製造に用いられ得るところから、血糖値降下
を期待し得る機能性食品が含まれる。機能性食品の形態
としては、例えば、ドリンク、飴、ガム、クッキーなど
を挙げることができる。
The pharmaceutical composition is preferably orally administered, and its form includes powders, granules, fine granules, capsules, tablets, pills, liquids and the like. The above-mentioned compounds and extracted extracts are components of beet sugar, and since they can be used for food production, functional foods that can be expected to lower blood glucose levels are included. Examples of the form of the functional food include drinks, candy, gums, cookies, and the like.

【0010】一般的には、テンサイ(北海道にて栽培)
の新鮮な根の水性抽出液を逆相SiO2カラムクロマトグ
ラフィー(ODSコスモジル、H2O−MeOH)および
通常のSiO2カラムクロマトグラフィー(CHCl3
MeOH−H2O)および最後にHPLC(YMC−パッ
クODS、MeOH−1%トリフルオロ酢酸)にかけ、
ベータブルガロシドI(1:新鮮な根から0.0061
%)、II(2:0.0004%)、III(3:0.0029
%)、およびIV(4:0.0005%)、さらに、チク
セツサポニンIVa(8:0.0002%)の分離を行っ
た。一方、ベータブルガロシドV(5:0.0011
%)は同様の分離方法により、テンサイの葉から分離す
る。また、通常用いられるMeOHまたはジアゾメタン
による処理方法を用いて、メチルエステル誘導体を得る
ことができる(ヘテロサイクルズ(Heterocycles)第41
巻第8号参照(投稿中))。
Generally, sugar beet (cultivated in Hokkaido)
Aqueous extracts of fresh roots of S. cerevisiae were subjected to reverse phase SiO 2 column chromatography (ODS Cosmozil, H 2 O-MeOH) and conventional SiO 2 column chromatography (CHCl 3 −).
MeOH-H 2 O) and finally subjected to HPLC (YMC-Pack ODS, MeOH-1% trifluoroacetic acid),
Beta bulgaroside I (1: 0.0061 from fresh root
%), II (2: 0.0004%), III (3: 0.0029)
%) And IV (4: 0.0005%), and further, Chixetusaponin IVa (8: 0.0002%) was separated. On the other hand, beta bulgaroside V (5: 0.0011
%) Is separated from sugar beet leaves by the same separation method. In addition, a methyl ester derivative can be obtained using a commonly used treatment method with MeOH or diazomethane (Heterocycles No. 41).
See Volume 8 (posting)).

【0011】薬理実験 ラットにおける血糖降下活性試験 体重125〜155gの雄ウイスターラットを水は自由
に接種させるが、20〜24時間絶食させた。被験化合
物を水に溶解し所定の各投与量を経口投与した(5ml/k
g)。30分後にD−グルコース(ブドウ糖)(5g/kg)
(ショ糖1.0g/kgでもよい)を経口投与した(5ml/k
g)。D−グルコース投与の0.5、1.0および2.0時間
後に、無麻酔拘束下に血液を頚動脈から採取し(0.4m
l)、氷水にて冷却後、遠心分離により血清を分離後、
血漿中のグルコース濃度をグルコースオキシダーゼ法に
て測定した。
Pharmacological Experiments Hypoglycemic Activity Test in Rats Male Wistar rats weighing 125-155 g were inoculated with water ad libitum, but they were fasted for 20-24 hours. The test compound was dissolved in water and orally administered at the prescribed doses (5 ml / k
g). After 30 minutes D-glucose (5 g / kg)
Oral administration of sucrose (1.0 g / kg is acceptable) (5 ml / k
g). Blood was collected from the carotid artery under unanesthetized restraint at 0.5, 1.0 and 2.0 hours after administration of D-glucose (0.4 m
l), after cooling with ice water, separating serum by centrifugation,
The glucose concentration in plasma was measured by the glucose oxidase method.

【0012】ベータブルガロシドI(1)、II(2)、
III(3)、IV(4)およびV(5)、およびプロサポ
ゲノール(6)のラットにおける経口ブドウ糖負荷試験
における血糖値の上昇での抑制効果を表1中に要約す
る。
Beta bulgaroside I (1), II (2),
Table 1 summarizes the inhibitory effects of III (3), IV (4) and V (5), and prosapogenol (6) on elevated blood glucose levels in the oral glucose tolerance test in rats.

【表1】 ベータブルガロシド I(1)、II(2)、III(3)、IV(4) およびV(5)、およびプロサポゲノール(6)の経口ブドウ糖負荷試験 における血糖値上昇抑制効果 投与量 ラット 血 糖 値 (mg/dl) (mg/kg, 数 0.5時間 1時間 2時間 経口) 正常群 10 72.4±3.3** 95.8±5.0** 90.6±4.8* 対照群 9 148.6±4.7 138.3±4.6 107.9±4.1 (76.2±4.7) (42.5±4.6) (17.3±4.1) 1 100 5 153.5±5.9 144.7±4.7 114.0±5.3 (81.1±5.9) (48.9±4.7) (23.4±5.3) 2 100 5 108.5±9.1** 137.7±5.4 121.8±4.9 (36.1±9.1**) (41.9±5.4) (31.2±4.9) 3 100 5 139.3±3.3 135.1±4.9 103.0±1.9 (66.9±3.3) (39.3±4.9) (12.4±1.9) 4 100 3 111.5±5.7** 125.8±5.9 114.0±0.6 (39.1±5.7**) (30.0±5.9) (23.4±0.6) 5 100 5 147.0±3.4 138.5±3.1 108.3±5.7 (74.6±3.4) (42.7±3.1) (17.7±5.7) 6 100 6 124.1±5.9** 139.3±4.8 119.3±3.0 (51.7±5.9**) (43.5±4.8) (28.7±3.0) *p<0.05,**p<0.01 各被験化合物はD−ブドウ糖(0.5g/kg)の経口
投与の30分前にラットに経口投与した。カッコ内の数
値は、正常な対照と各被験化合物処置間の血糖値(血漿
ブドウ糖濃度)の差異を示す。
[Table 1] Administration of beta-bulgaroside I (1), II (2), III (3), IV (4) and V (5), and prosapogenol (6) in blood glucose tolerance test in oral glucose tolerance test Amount Rat blood glucose level (mg / dl) (mg / kg, number 0.5 hours 1 hour 2 hours Oral) Normal group 10 72.4 ± 3.3 ** 95.8 ± 5.0 ** 90.6 ± 4.8 * Control group 9 148.6 ± 4.7 138.3 ± 4.6 107.9 ± 4.1 (76.2 ± 4.7) (42.5 ± 4.6) (17.3 ± 4.1) 1 100 5 153.5 ± 5.9 144.7 ± 4.7 114.0 ± 5.3 (81.1 ± 5.9) (48.9 ± 4.7) (23.4 ± 5.3) 2 100 5 108.5 ± 9.1 ** 137.7 ± 5.4 121.8 ± 4.9 (36.1 ± 9.1 **) (41.9 ± 5.4) (31.2 ± 4.9) 3 100 5 139.3 ± 3.3 135.1 ± 4.9 103.0 ± 1.9 (66.9 ± 3.3) (39.3 ± 4.9) (12.4 ± 1.9) 4 100 3 111.5 ± 5.7 ** 125.8 ± 5.9 114.0 ± 0.6 (39.1 ± 5.7 **) (30.0 ± 5.9) (23.4 ± 0.6) 5 100 5 147.0 ± 3.4 138.5 ± 3.1 108.3 ± 5.7 (74.6 ± 3.4) (42.7 ± 3.1) (17.7 ± 5.7) 6 100 6 124.1 ± 5.9 ** 139.3 ± 4.8 119.3 ± 3.0 (51.7 ± 5.9 **) (43.5 ± 4.8) (28.7 ± 3.0) * p <0.05, ** p <0.01 Each test compound was orally administered to rats 30 minutes before the oral administration of D-glucose (0.5 g / kg). Numbers in parentheses indicate the difference in blood glucose level (plasma glucose concentration) between normal control and each test compound treatment.

【0013】ブドウ糖負荷試験において、ベータブルガ
ロシド II(2)、III(3)およびIV(4)、プロサポ
ゲノール(6)は低血糖活性を示した。3−O−モノデ
スモシド(2、4、6)が、3,28−O−ビスデスモ
シド(3)よりもさらに強力な活性を示したことは注目
すべきである。これは構造と低血糖活性の特徴化を示唆
するものと思われる。
In the glucose tolerance test, beta bulgaroside II (2), III (3) and IV (4), prosapogenol (6) showed hypoglycemic activity. It is noteworthy that 3-O-monodesmoside (2,4,6) showed even more potent activity than 3,28-O-bisdesmoside (3). This may suggest characterization of structure and hypoglycemic activity.

【0014】本発明の式AおよびBで示されるベータブ
ルガロシド類化合物およびテンサイの抽出エキスは低血
糖活性を示し、血糖降下剤として有用である。また、一
般に生体内において遊離形と実質的に同様の生理活性ま
たは薬理活性を発揮するもの、例えば、本発明の化合物
の誘導体および医薬的に許容される塩、付加塩、水和物
などは本発明の技術的範囲の含まれるものである。
The beta-bulgaroside compounds represented by the formulas A and B of the present invention and the extract of sugar beet exhibit hypoglycemic activity and are useful as hypoglycemic agents. In addition, those that exhibit substantially the same physiological activity or pharmacological activity as the free form in vivo, for example, derivatives of the compound of the present invention and pharmaceutically acceptable salts, addition salts, hydrates, etc. It is within the technical scope of the invention.

【0015】投与方法としては経口、非経口のいずれで
もよいが、経口投与が好ましい。経口投与医薬組成物の
調製にあたっては、通常用いられる製薬学的に許容され
得る添加剤(担体、賦形剤、崩壊剤、滑沢剤、結合剤、
表面活性剤、防腐剤、懸濁化剤、着香料等)を用いるこ
とができる。ベータブルガロシド類化合物は毒性が低い
ため投与量に特に制限はない。
The method of administration may be oral or parenteral, but oral administration is preferred. In preparing an orally administered pharmaceutical composition, a commonly used pharmaceutically acceptable additive (carrier, excipient, disintegrant, lubricant, binder,
Surfactants, preservatives, suspending agents, flavoring agents, etc.) can be used. The beta bulgaroside compound has low toxicity and therefore the dose is not particularly limited.

【0016】[0016]

【実施例】【Example】

実施例1 テンサイからベータブルガロシドI〜Vの分
離 細切したテンサイ[北海道産(1994年度)新鮮根、
12kg]に50%含水メタノール(エタノールでもよ
い)(10リットル)を加え、加熱還流下3時間抽出す
る。抽出液を濾別した後、残渣に50%含水メタノール
(10リットル)を加え同様の抽出操作を計3回行う。
抽出液を合わし、減圧下メタノールを留去した後、凍結
乾燥して含水メタノール抽出エキス(2kg)を得た。
含水メタノール抽出エキスを逆相シリカゲルカラム[C
hromatorex ODS(Fuji Silysia Chemical LT
D.)、2kg]に付し、水で溶出してショ糖を除いた
後、メタノール(エタノールでもよい)で溶出してメタ
ノール溶出部(粗サポニン分画、15g)を得た。
Example 1 Isolation of beta bulgaroside IV from sugar beet Shredded sugar beet [fresh roots from Hokkaido (1994),
12 kg] is added with 50% water-containing methanol (or ethanol) (10 liters), and the mixture is extracted with heating under reflux for 3 hours. After the extract is filtered off, 50% hydrous methanol (10 liters) is added to the residue and the same extraction operation is performed three times in total.
The extracts were combined, the methanol was distilled off under reduced pressure, and the extract was freeze-dried to obtain a hydrous methanol extract (2 kg).
Extract the hydrous methanol extract with a reversed-phase silica gel column [C
hromatorex ODS (Fuji Silysia Chemical LT
D.), 2 kg], and eluted with water to remove sucrose, and then eluted with methanol (or ethanol) to obtain a methanol elution portion (crude saponin fraction, 15 g).

【0017】メタノール溶出部をシリカゲルカラムクロ
マトグラフィー[silica gel 60(Merck)]に付し、
クロロホルム−メタノール水混液で溶出して、クロロホ
ルム−メタノール水混液[7:3:1(下層)]溶出部
(Fr.2、2.05g)とクロロホルム−メタノール水
混液(6:4:1)溶出部(Fr.4、0.6g)を得
た。Fr.2及びFr.4は更にシリカゲルカラムクロマ
トグラフィー[silicagel 60 Fr.2へは220
g、Fr.4へは70g、クロロホルム−メタノール水
混液]で分離した後、高速液体クロマトグラフィー[装
置:Shimadzu LC−10AS(島津社製)、カラム:
YMC−Pack ODS−A(YMC Co.,Ltd.)、溶出
溶媒:75%メタノール−1%トリフッ化酢酸]で精製
してベータブルガロシドI(0.0061%)、II(0.
0004%)、III(0.0029%)、IV(0.000
5%)及びchikusetsusaponin IVa(0.0002%)を
得た。
The elution part of methanol was subjected to silica gel column chromatography [silica gel 60 (Merck)],
Elute with chloroform-methanol water mixture, then eluate chloroform-methanol water mixture [7: 3: 1 (lower layer)] elution part (Fr. 2.05g) with chloroform-methanol water mixture (6: 4: 1). Part (Fr. 4, 0.6 g) was obtained. Fr. 2 and Fr. 4 is silica gel column chromatography [silicagel 60 Fr. 220 to 2
g, Fr. After separating with 4 to 70 g, mixed solution of chloroform-methanol water, high performance liquid chromatography [apparatus: Shimadzu LC-10AS (manufactured by Shimadzu), column:
YMC-Pack ODS-A (YMC Co., Ltd.), elution solvent: 75% methanol-1% trifluoroacetic acid] and purified to obtain beta bulgaroside I (0.0061%), II (0.006%).
0004%), III (0.0029%), IV (0.000)
5%) and chikusetsusaponin IVa (0.0002%).

【0018】一方、細切したテンサイ新鮮葉(2.6k
g)を新鮮根の場合と同様に含水メタノール抽出(5リ
ットル×3回)して含水メタノール抽出エキス(115
g)を得た。含水メタノール抽出エキスを逆相シリカゲ
ルカラムクロマトグラフィ−に付し、メタノール溶出部
(粗サポニン分画、8.6g)を得た。メタノール溶出
部をシリカゲルカラムクロマトグラフィー、ついで高速
液体クロマトグラフィー(いずれも根と同条件)で分離
精製してベータブルガロシド V(0.0011%)を得
た。
On the other hand, freshly chopped sugar beet leaves (2.6k
g) was extracted with hydrous methanol (5 liters x 3 times) as in the case of fresh roots, and the hydrous methanol extract (115
g) was obtained. The extract containing water-containing methanol was subjected to reverse phase silica gel column chromatography to obtain a methanol eluate (crude saponin fraction, 8.6 g). The methanol eluate was separated and purified by silica gel column chromatography and then high performance liquid chromatography (all under the same conditions as the root) to obtain beta bulgaroside V (0.0011%).

【0019】ベータブルガロシドI(1) 式A(式中、R1はβ−D−Gluであり、R3およびR4
Hである)で示される。無色微細結晶、mp215〜21
7℃ [α]D+44.9°(MeOH) 正モードFAB−MS:m/z977(M+Na)+
477020Na、 負モードFAB−MS:953(M−H)-4769
20 1 H NMR(ピリジン−d5) IR(KBr):3453、1740、1736、10
78cm-1 メタノール分解(9%HCl−MeOH、還流)により、
オレアノール酸、メチル−D−グルコシドおよびメチル
−D−グルクロニドを分離した。
Beta bulgaroside I (1) is represented by Formula A where R 1 is β-D-Glu and R 3 and R 4 are H. Colorless fine crystals, mp215-21
7 ° C. [α] D + 44.9 ° (MeOH) Positive mode FAB-MS: m / z 977 (M + Na) +
C 47 H 70 O 20 Na, negative mode FAB-MS: 953 (M- H) - C 47 H 69
O 20 1 H NMR (pyridine -d 5) IR (KBr): 3453,1740,1736,10
78 cm -1 methanol decomposition (9% HCl-MeOH, reflux)
Oleanolic acid, methyl-D-glucoside and methyl-D-glucuronide were separated.

【0020】ベータブルガロシドI−1"'−メチルエス
テル(1a) 式A(式中、R1はβ−D−Gluであり、R3はHであり、
4はCH3である)で示される。 無色微細結晶 mp200〜202℃ [α]D+57.3°(MeOH) 正モードFAB−MS:m/z991(M+Na)+48
7220Na IR(KBr):3474、1743、1736、10
76cm-1 1 H NMR(ピリジン−d5):δ3.28(dd-like,3
−H),5.00(d,J=7.6,1'−H),4.72
(m,3'−H),5.38(m,4'−H),5.82(s,3"
−H),4.63(s,2"'−H2),6.33(d,J=7.
9,1""−H) (1a)のHMBCデータで1"'−OCH3および1"'
−C間に遠隔スピン結合が観察され、(1a)の1"'−
メチル化構造を確認した。最後に、MeOH中過剰のジ
アゾメタンでの1のメチル化は、6',1",2",1"'−テ
トラ−O−メチル誘導体(1b)を生成し、アキラント
シド A(achyranthoside A)メチルエステル(イダ
ら、テトラヘドロン・レターズ35巻6887頁(19
94年))と同定した。上記の結果に基づいてベータブ
ルガロシド I(1)およびII(2)の構造を決定し
た。
Beta bulgaroside I-1 "'-methyl ester (1a) Formula A wherein R 1 is β-D-Glu, R 3 is H,
R 4 is represented by CH 3 a is). Colorless fine crystals mp 200 to 202 ° C. [α] D + 57.3 ° (MeOH) Positive mode FAB-MS: m / z 991 (M + Na) + C 48
H 72 O 20 Na IR (KBr): 3474, 1743, 1736, 10
76cm -1 1 H NMR (pyridine -d 5): δ3.28 (dd- like, 3
-H), 5.00 (d, J = 7.6, 1'-H), 4.72
(m, 3'-H), 5.38 (m, 4'-H), 5.82 (s, 3 "
-H), 4.63 (s, 2 "'- H 2), 6.33 (d, J = 7.
9,1 ""-H) 1 "'-OCH 3 and 1"' in HMBC data of (1a)
Remote spin coupling was observed between -C, 1 "'-of (1a)
The methylated structure was confirmed. Finally, methylation of 1 with an excess of diazomethane in MeOH produced the 6 ', 1 ", 2", 1 "'-tetra-O-methyl derivative (1b), which was the achillanthoside A (achyranthoside A) methyl ester. (Ida et al., Tetrahedron Letters, Vol. 35, page 6887 (19
1994)). The structures of beta bulgaroside I (1) and II (2) were determined based on the above results.

【0021】ベータブルガロシドII(2) 式A(式中、R1、R3およびR4はHである)で示され
る。(1)のアルカリ加水分解(5%aq.NaOH、還
流)により、ベータブルガロシドII(2)が得られた。 無色微細結晶 mp173〜174℃ [α]D+98.0°(MeOH) 負モードFAB−MS:m/z791(M−H)-
415915 IR(KBr):3432、1741、1731、10
80cm-11 H NMR(ピリジン−d5):δ3.30(dd-like,3
−H),4.99(d,J=7.3,1'−H),4.85(m,
3'−H),5.38(dd-like,4'−H),5.99(s,
3"−H),4.80(m,2"'−H2)1 H NMR(ピリジン−d5)および(1)および
(2)の13C NMR(表2参照)をCOSY(1H−1
H,1H−13C)、HOHAHAおよびROESY実験
により帰属させ、3−オキソピルビン酸およびグリコー
ル酸からなるビス−アセタールグルクロニド部分の存在
を示した[(1):δ5.00(d,J=7.3,1'−
H),4.75(m,3'−H),5.38(dd-like,4'−
H),5.99(s,3"−H),4.80(m,2"'−
2)]。(1)における3−O−グルクロニド部分のC
−3'および4'位のビス−アセタール構造をHMBC実
験により確認した。すなわち、(1)の下記の炭素およ
びプロトン間に遠隔スピン結合が存在する(1'−Hお
よび3−C;3'−Hおよび3"−C;3"−Hおよび3'
−C,2"'−C;4'−Hおよび2"−C;2"'−H2
よび3"−C,1"'−C)。還流下MeOHで処理するこ
とにより、(1)は容易に1"'−メチルエステル(1
a)に変化し、弱アルカリ加水分解[2%aq.K2CO3
−CH3CN(1:1),r.t.]で(1)に戻った。
Beta bulgaroside II (2) is represented by the formula A (wherein R 1 , R 3 and R 4 are H). Alkaline hydrolysis of (1) (5% aq. NaOH, reflux) gave beta bulgaroside II (2). Colorless microcrystals mp173~174 ℃ [α] D + 98.0 ° (MeOH) negative mode FAB-MS: m / z791 ( M-H) - C
41 H 59 O 15 IR (KBr): 3432, 1741, 1731, 10
80 cm -1 ) 1 H NMR (pyridine-d 5 ): δ3.30 (dd-like, 3
-H), 4.99 (d, J = 7.3, 1'-H), 4.85 (m,
3'-H), 5.38 (dd-like, 4'-H), 5.99 (s,
3 "-H), 4.80 (m , 2"'- H 2) 1 H NMR ( pyridine -d 5) and (1) and (2) of 13 C NMR (see Table 2) COZY (1 H − 1
H, 1 H- 13 C), HOHAHA and ROESY experiments, and showed the presence of a bis-acetal glucuronide moiety consisting of 3-oxopyruvic acid and glycolic acid [(1): δ 5.00 (d, J = 7.3, 1'-
H), 4.75 (m, 3'-H), 5.38 (dd-like, 4'-
H), 5.99 (s, 3 "-H), 4.80 (m, 2"'-
H 2 )]. C of the 3-O-glucuronide moiety in (1)
The bis-acetal structures at the 3'and 4'positions were confirmed by HMBC experiments. That is, there is a remote spin bond between the following carbon and proton of (1) (1'-H and 3-C; 3'-H and 3 "-C;3" -H and 3 '.
-C, 2 "'-C;4'-H and 2"-C; 2. "' - H 2 and 3" -C, 1 "'- by C) treating at reflux MeOH, (1) Is easily converted into 1 "'-methyl ester (1
a), weak alkaline hydrolysis [2% aq. K 2 CO 3
-CH 3 CN (1: 1) , and returned to at rt] (1).

【0022】ベータブルガロシド III(3) 式B(式中、R1はβ−D−Gluであり、R2、R3および
4はHである)で示される。 無色微細結晶 mp212〜214℃ [α]D+11.0°(MeOH) 正モードFAB−MS:m/z979(M+Na)+
477220Na 負モードFAB−MS:m/z955(M−H)-
477120 1 H NMR(ピリジン−d5):δ3.55(dd-like,3
−H),4.98(d,J=7.6,1'−H),4.51(m,
3'−H),4.65(m,4'−H),5.34(brs,2"−
H),6.31(br s,3"−H),5.06,5.35(AB
q,J=16.5,2"'−H2) IR(KBr):3429、1742、1736、10
76cm-1
Beta bulgaroside III (3) is represented by Formula B, where R 1 is β-D-Glu and R 2 , R 3 and R 4 are H. Colorless fine crystals mp212-214 ° C [α] D + 11.0 ° (MeOH) Positive mode FAB-MS: m / z 979 (M + Na) +
C 47 H 72 O 20 Na negative mode FAB-MS: m / z955 ( M-H) - C
47 H 71 O 20 1 H NMR ( pyridine -d 5): δ3.55 (dd- like, 3
-H), 4.98 (d, J = 7.6, 1'-H), 4.51 (m,
3'-H), 4.65 (m, 4'-H), 5.34 (brs, 2 "-
H), 6.31 (brs, 3 "-H), 5.06, 5.35 (AB
q, J = 16.5, 2 "'-H2) IR (KBr): 3429, 1742, 1736, 10
76 cm -1 )

【0023】(3)のMeOH処理は1"'−メチルエス
テル(3a)が生成し、これは弱アルカリ加水分解で
(3)に戻った。1"'−メチルエステル構造(3a)は
(3a)の1"'−OCH3および1"'−C間のHMBC
相関関係の観察されたことにより確認された。(3)の
1H NMRおよび13C NMRと(3a)および(4)
1H NMRおよび13C NMRの詳細な比較により
(表2参照)、ベータブルガロシド III(3)およびIV
(4)の構造式が決定された。
Treatment of (3) with MeOH produced 1 "'-methyl ester (3a) which was hydrolyzed back to (3). The 1"'-methyl ester structure (3a) was converted to (3a). ) HMBC between 1 "'-OCH 3 and 1"'-C
This was confirmed by the observed correlation. Of (3)
1 H NMR and 13 C NMR and (3a) and (4)
By detailed 1 H and 13 C NMR comparisons (see Table 2) of beta bulgaroside III (3) and IV
The structural formula of (4) was determined.

【0024】ベータブルガロシド III−1"'−メチルエ
ステル(3a) 式B(式中、R1はβ−D−Gluであり、R2およびR3
Hであり、R4はCH3である)で示される。 無色微細結晶 mp191〜192℃ [α]D+13.5°(MeOH) 負モードFAB−MS:m/z969(M−H)-48
7320 IR(KBr):3410、1740、1736、10
76cm-1 1 H NMR(ピリジン−d5):δ3.34(dd-like,3
−H),4.97(d,J=7.6,1'−H),4.46(m,
3'−H),4.46(m,3'−H),4.60(m,4'−
H),5.40(br s,2"−H),6.25(br s,3"−
H),4.92,5.33(ABq,J=16.5,2"'−H
2),6.33(d,J=7.6,1""−H)ヘ゛ータフ゛ルカ゛ロシト゛ IIIは部分的酸加水分解により化合物O(I.
Yoshioka,M.Fujio,M.Osamura,I.Kitagawa,Tetra
hedron Lett.,1966,6303)を生成した。他方、(3)の
アルカリ加水分解でベータブルガロシド IV(4)を生
成した。
Beta bulgaroside III-1 "'-methyl ester (3a) Formula B wherein R 1 is β-D-Glu, R 2 and R 3 are H, R 4 is CH 3 . represented by a is) colorless microcrystals mp191~192 ℃ [α] D + 13.5 ° (MeOH) negative mode FAB-MS: m / z969 ( M-H) - C 48
H 73 O 20 IR (KBr): 3410, 1740, 1736, 10
76cm -1 1 H NMR (pyridine -d 5): δ3.34 (dd- like, 3
-H), 4.97 (d, J = 7.6, 1'-H), 4.46 (m,
3'-H), 4.46 (m, 3'-H), 4.60 (m, 4'-
H), 5.40 (br s, 2 "-H), 6.25 (br s, 3"-
H), 4.92, 5.33 (ABq, J = 16.5, 2 "'-H
2 ), 6.33 (d, J = 7.6, 1 ""-H) data valgologide III is a compound O (I.
Yoshioka, M. Fujio, M. Osamura, I. Kitagawa, Tetra
hedron Lett., 1966 , 6303). On the other hand, beta-bulgaroside IV (4) was produced by alkaline hydrolysis of (3).

【0025】ベータブルガロシド IV(4) 式B(式中、R1、R2、R3およびR4はHである)で示さ
れる。 無色微細結晶 mp186〜187℃ [α]D+10.4°(MeOH) 負モードFAB−MS:m/z793(M−H)-
416115 1 H NMR(ピリジン−d5):δ3.37(dd-like,3
−H),5.00(d,J=5.9,1'−H),4.52(m,
3'−H),4.68(m,4'−H),5.34(brs,2"−
H),6.34(br s,3"−H),5.07,5.38(AB
q,J=16.7,2"'−H2) IR(KBr):30,34、1740、1736、1
076cm-1
Beta bulgaroside IV (4) is represented by Formula B (wherein R 1 , R 2 , R 3 and R 4 are H). Colorless microcrystals mp186~187 ℃ [α] D + 10.4 ° (MeOH) negative mode FAB-MS: m / z793 ( M-H) - C
41 H 61 O 15 1 H NMR ( pyridine -d 5): δ3.37 (dd- like, 3
-H), 5.00 (d, J = 5.9, 1'-H), 4.52 (m,
3'-H), 4.68 (m, 4'-H), 5.34 (brs, 2 "-
H), 6.34 (brs, 3 "-H), 5.07, 5.38 (AB
q, J = 16.7, 2 "'-H2) IR (KBr): 30, 34, 1740, 1736, 1
076 cm -1 )

【0026】(3)および(4)の1H NMR12)およ
13C NMR(表2参照)スペクトルは、(3)の3
−O−グルクロニド部分の3'−ヒドロキシル基にタル
トロンアルデヒド酸およびグリコール酸からなるアセタ
ール置換基の存在を示した(HMBCの関係:1'−H
および3−C;3"−Hおよび3'−C;2"'−C;2"
−Hおよび1"−C,3"−C;2"'−H2および3”−
C,1"'−C)。この結果および(3)とチクセツサポ
ニンIVa(I.Yoshioka,M.Fujio,M.Osamura,I.
Kitagawa,Tetrahedron Lett.,1966,6303)の13C NM
Rデータの比較に基づいて(3)の構造を決定した。
The 1 H NMR 12) and 13 C NMR (see Table 2) spectra of (3) and (4) are the same as those of (3).
The presence of an acetal substituent consisting of tartronaldehyde acid and glycolic acid was shown at the 3'-hydroxyl group of the -O-glucuronide moiety (HMBC relationship: 1'-H.
And 3-C; 3 "-H and 3'-C;2"'-C; 2 "
-H and 1 "-C, 3"-C; 2 "'- H 2 and 3" -
C, 1 "'-C). The results and (3) and Chixetusaponin IVa (I. Yoshioka, M. Fujio, M. Osamura, I.
Kitagawa, Tetrahedron Lett., 1966 , 6303) 13 C NM
The structure of (3) was determined based on comparison of R data.

【0027】ベータブルガロシドV(5) 式B(式中、R1およびR2はβ−D−Gluであり、R3
よびR4はHである)で示される。 無色微細結晶 mp205〜206℃ [α]D+23.8°(MeOH) 正モードFAB−MS:m/z1141(M+Na)+
538225Na 負モードFAB−MS:m/z1117(M−H)-
538125 IR(KBr):3432、1740、1736、10
76cm-1 5の1H NMRおよび13C NMR(表2参照)データ
は、2'−O−β−D−グルコピラノシル[δ5.69
(d,J=7.3,1""'−H)]および3'−O−アセタル
置換基[δ4.40(m,3'−H),4.63(m,4'−
H)]を有する3−O−グルクロニド部分[δ4.97
(d,J=8.9,1'−H)]の存在を示し、タルトロン
アルデヒド酸[δ5.38(brs,2"−H),(brs,3"−
H)]およびグリコール酸[δ4.92,5.17(AB
q,J=16.1,2"'−H2)]から構成された。HMB
C相関を、以下のプロトンとカーボン(1'−Hおよび
3−C;1""'−Hおよび2'−C;3"−Hおよび3'−
C;2"−C;2"'−C;2"−Hおよび1"−C,2"'
−Hおよび1"'−C)の間で観察した。この証拠および
5とチクセツサポニン V(T.D.Lin,N.Kndo,J.S
hoji, Chem,Pharm.Bull.,24,253(1976))に基づいて5
の構造を推測した。
Beta bulgaroside V (5) is represented by Formula B where R 1 and R 2 are β-D-Glu and R 3 and R 4 are H. Colorless fine crystals mp 205 to 206 ° C. [α] D + 23.8 ° (MeOH) Positive mode FAB-MS: m / z 1141 (M + Na) +
C 53 H 82 O 25 Na Negative mode FAB-MS: m / z 1117 (M−H)
C 53 H 81 O 25 IR (KBr): 3432, 1740, 1736, 10
1 H NMR and 13 C NMR (see Table 2) data of 76 cm −1 5 are obtained by 2′-O-β-D-glucopyranosyl [δ5.69.
(d, J = 7.3, 1 ""'-H)] and 3'-O-acetal substituents [δ4.40 (m, 3'-H), 4.63 (m, 4'-).
H)] having a 3-O-glucuronide moiety [δ4.97
(d, J = 8.9, 1'-H)], and tartraldehyde acid [δ5.38 (brs, 2 "-H), (brs, 3"-).
H)] and glycolic acid [δ 4.92, 5.17 (AB
q, J = 16.1,2 "'- .HMB constructed from H 2)]
The C correlation was determined by the following proton and carbon (1'-H and 3-C; 1 ""'-H and 2'-C; 3 "-H and 3'-
C; 2 "-C;2"'-C; 2 "-H and 1" -C, 2 "'
-H and 1 "'-C). This evidence and 5 and Chixetusaponin V (T.D. Lin, N. Kndo, J.S.
hoji, Chem, Pharm.Bull., 24 , 253 (1976)) 5
Guessed the structure of.

【0028】(5)のMeOH処理により1"'−メチル
エステル(5a)が得られ、これは弱アルカリ加水分解
で(5)に戻った。1"'−メチルエステル構造(5a)
をHMBC実験により確認した。他方、(5)のジアゾ
メタンによるメチル化によりテトラメチル誘導体(5
b)が得られ、(5)をアルカリ加水分解することによ
りプロサポゲノール(6)が得られた。これらの結果お
よび(5)の1H NMRと13C NMRデータと(5
a)、(5b)および(6)の1H NMRと13C NM
Rデータの比較に基づいて、ベータブルガロシド V
(5)を構造決定した。
Treatment of (5) with MeOH provided 1 "'-methyl ester (5a) which was hydrolyzed back to (5). 1"'-methyl ester structure (5a).
Was confirmed by the HMBC experiment. On the other hand, the methylation of (5) with diazomethane gives the tetramethyl derivative (5
b) was obtained, and prosapogenol (6) was obtained by alkaline hydrolysis of (5). These results and the 1 H NMR and 13 C NMR data of (5) and (5
a), (5b) and (6) 1 H NMR and 13 C NM
Beta Bulgaroside V based on comparison of R data
The structure of (5) was determined.

【0029】ベータブルガロシド V−1"'−メチルエ
ステル(5a) 式B(式中、R1およびR2はβ−D−Gluであり、R3
Hであり、R4はCH3である)で示される。 無色微細結晶、mp211〜213℃ [α]D+26.6°(MeOH) 正モードFAB−MS:m/z1155(M+Na)+
548425Na IR(KBr):3473,1742,1736,107
6cm-1 1 H NMR(ピリジン−d5):δ3.26(dd-like,3−
H),4.99(d,J=6.9,1'−H),4.43(m,3'
−H),4.60(m,4'−H),5.41(br s,2"−
H),6.36(br s,3"−H),4.77,5.69(AB
q,J=16.5,2"'−H2),6.33(d,J=7.9,
1""−H),5.69(d,J=7.3,1""'−H)
Beta bulgaroside V-1 "'-methyl ester (5a) Formula B (wherein R 1 and R 2 are β-D-Glu, R 3 is H, R 4 is CH 3 Colorless fine crystals, mp 211-213 ° C. [α] D + 26.6 ° (MeOH) Positive mode FAB-MS: m / z 1155 (M + Na) +
C 54 H 84 O 25 Na IR (KBr): 3473, 1742, 1736, 107
6cm -1 1 H NMR (pyridine -d 5): δ3.26 (dd- like, 3-
H), 4.99 (d, J = 6.9, 1'-H), 4.43 (m, 3 '
-H), 4.60 (m, 4'-H), 5.41 (br s, 2 "-
H), 6.36 (brs, 3 "-H), 4.77, 5.69 (AB
q, J = 16.5, 2 "'-H2), 6.33 (d, J = 7.9,
1 ""-H), 5.69 (d, J = 7.3, 1 ""-H)

【0030】ベータブルガロシド V−テトラメチルエ
ステル(5b) 式B(式中、R1およびR2はβ−D−Gluであり、R3
よびR4はCH3である)で示される。 無色微細結晶 mp155〜157℃ [α]D+38.2°(MeOH) 正モードFAB−MS:m/z1197(M+Na)+
579025Na IR(KBr):3432、1747、1736、107
6cm-1 1 H NMR(ピリジン−d5):δ3.21(dd-like,3−
H),5.00(d-like,1'−H),4.42(m,3'−
H),4.38(m,4'−H),4.80(br s,2"−H),
6.10(br s,3"−H),4.76,5.08(ABq,J
=16.3,2"'−H2),6.35(d,J=7.6,1""
−H),5.42(d,J=7.2,1""'−H)
Beta bulgaroside V-tetramethyl ester (5b) is represented by Formula B, where R 1 and R 2 are β-D-Glu and R 3 and R 4 are CH 3 . Colorless fine crystals mp155-157 ° C. [α] D + 38.2 ° (MeOH) Positive mode FAB-MS: m / z 1197 (M + Na) + C
57 H 90 O 25 Na IR (KBr): 3432, 1747, 1736, 107
6cm -1 1 H NMR (pyridine -d 5): δ3.21 (dd- like, 3-
H), 5.00 (d-like, 1'-H), 4.42 (m, 3'-
H), 4.38 (m, 4'-H), 4.80 (brs, 2 "-H),
6.10 (br s, 3 "-H), 4.76, 5.08 (ABq, J
= 16.3,2 "'- H 2) , 6.35 (d, J = 7.6,1""
-H), 5.42 (d, J = 7.2, 1 ""'-H)

【0031】プロサポゲノール(6) 式B(式中、R1はHであり、R2はβ−D−Gluであり、
3およびR4はHである)で示される。 無色微細結晶、mp174〜176℃ [α]D+30.0°(MeOH) 負モードFAB−MS:m/z955(M−H)-47
7120 IR(KBr):3432,1748,1736,10
78cm-1 1 H NMR(ピリジン−d5):δ3.38(dd-like,3
−H),4.99(d,J=7.0,1'−H),4.48(m,
3'−H),4.52(m,4'−H),5.41(brs,2"−
H),6.35(br s,3"−H),4.94,5.21(AB
q,J=16.2,2"'−H2),5.72(d,J=7.6,
1""'−H)
Prosapogenol (6) Formula B (wherein R 1 is H, R 2 is β-D-Glu,
R 3 and R 4 are H). Colorless fine crystals, mp174~176 ℃ [α] D + 30.0 ° (MeOH) negative mode FAB-MS: m / z955 ( M-H) - C 47
H 71 O 20 IR (KBr): 3432, 1748, 1736, 10
78cm -1 1 H NMR (pyridine -d 5): δ3.38 (dd- like, 3
-H), 4.99 (d, J = 7.0, 1'-H), 4.48 (m,
3'-H), 4.52 (m, 4'-H), 5.41 (brs, 2 "-
H), 6.35 (brs, 3 "-H), 4.94, 5.21 (AB
q, J = 16.2, 2 "'-H2), 5.72 (d, J = 7.6.
1 ""'-H)

【0032】[0032]

【表2】 ベータブルガロシド I(1)、II(2)、III(3)、IV(4) およびV(5)および関連化合物(1a,3a,5a,5b,6)* のための13C NMRデータ 1 1a 2 3 3a 4 5 5a 5b 6 C-1 38.4 38.5 38.5 38.6 38.6 38.6 38.6 38.6 38.6 38.5 C-2 26.4 26.5 26.5 26.6 26.6 26.6 26.4 26.5 26.5 26.5 C-3 89.2 89.4 89.3 89.2 89.2 89.2 89.5 89.5 89.6 89.3 C-4 39.3 39.5 39.5 39.5 39.5 39.5 39.5 39.5 39.5 39.5 C-5 55.5 55.6 55.7 55.7 55.7 55.7 55.8 55.8 55.6 55.7 C-6 18.3 18.5 18.4 18.5 18.5 18.4 18.5 18.5 18.5 18.4 C-7 33.0 33.0 33.3 33.1 33.1 33.1 33.1 33.1 33.2 33.3 C-8 39.7 39.9 39.7 39.9 39.9 39.7 39.9 39.9 39.9 39.7 C-9 47.8 47.9 47.9 48.0 48.0 48.0 48.0 48.0 48.0 47.9 C-10 36.7 36.9 36.9 36.9 36.9 36.9 36.9 36.9 36.9 36.9 C-11 23.2 23.4 23.8 23.4 23.4 23.4 23.4 23.4 23.2 23.8 C-12 122.7 122.9 122.5 122.8 122.8 122.5 122.8 122.8 122.9 122.5 C-13 144.0 144.1 144.8 144.1 144.1 144.8 144.1 144.1 144.2 144.8 C-14 42.0 42.1 42.1 42.1 42.1 42.2 42.1 42.1 42.2 42.1 C-15 28.1 28.2 28.3 28.2 28.2 28.3 28.2 28.2 28.3 28.3 C-16 23.6 23.7 23.8 23.7 23.7 23.8 23.6 23.7 23.7 23.8 C-17 46.8 47.0 46.6 47.0 47.0 46.7 47.0 47.0 47.0 46.6 C-18 41.6 41.8 42.0 41.7 41.7 42.0 41.7 41.7 41.8 42.0 C-19 46.0 46.0 46.4 46.4 46.2 46.4 46.2 46.1 46.0 46.4 C-20 30.6 30.8 31.0 30.7 30.8 31.0 30.7 30.8 30.8 31.0 C-21 33.8 34.0 34.2 34.0 34.0 34.2 34.0 34.0 34.0 34.2 C-22 32.4 32.5 33.2 32.5 32.5 32.1 32.5 32.5 32.6 33.2 C-23 27.9 28.0 28.1 28.1 28.1 28.2 28.0 28.0 28.0 28.1 C-24 16.7 16.9 16.9 16.9 16.9 16.9 16.7 16.7 16.8 16.9 C-25 15.3 15.5 15.4 15.5 15.5 15.4 15.5 15.5 15.5 15.4 C-26 17.3 17.4 17.3 17.4 17.4 17.4 17.4 17.4 17.6 17.3 C-27 26.0 26.1 26.2 26.1 26.1 26.2 26.1 26.1 26.1 26.2 C-28 176.3 176.4 180.1 176.4 176.4 180.2 176.4 176.4 176.4 180.1 C-29 33.0 33.0 33.3 32.1 33.1 33.1 33.1 33.1 33.2 33.3 C-30 23.5 23.6 23.8 23.6 23.6 23.8 23.4 23.6 23.4 23.8 3-O-Gluc.A C-1' 107.4 107.6 107.6 106.7 106.8 106.8 105.1 105.2 104.8 105.3 C-2' 71.9 72.0 72.1 74.8 74.7 74.8 78.3 78.2 79.1 78.3 C-3' 72.4 72.5 72.5 85.4 85.1 85.5 83.9 82.9 84.0 83.9 C-4' 70.0 70.1 70.1 72.3 72.3 72.4 72.9 73.2 71.1 72.9 C-5' 75.1 75.3 75.3 77.5 77.5 77.6 77.2 77.2 76.5 77.3 C-6' 171.4 171.4 171.6 172.4 172.4 172.4 172.2 172.3 170.3 172.2 6'-OMe 51.9 C-1" 171.0 171.1 171.2 174.8 174.6 174.6 174.5 177.4 170.3 174.5 1"-OMe 52.1 C-2" 93.8 93.8 94.0 74.2 74.2 74.2 73.0 72.6 82.8 72.8 2"-OMe 58.9 C-3" 97.9 98.2 98.1 105.4 104.9 105.4 105.2 104.6 102.3 105.2 C-1"' 172.2 170.0 172.3 173.9 171.3 173.9 173.7 171.0 170.3 173.7 1"'-OMe 51.5 51.3 51.2 51.4 C-2"' 64.7 64.5 64.9 65.1 64.2 64.3 65.7 64.8 64.1 65.7 28-O-Glu. C-1"" 95.7 95.7 95.7 95.7 95.7 95.7 95.8 C-2"" 74.0 74.1 74.1 74.1 74.1 74.1 74.2 C-3"" 78.7 78.9 78.8 78.9 78.8 78.9 79.0 C-4"" 70.9 71.1 71.1 71.1 71.1 71.1 71.1 C-5"" 79.1 79.3 79.3 79.3 79.2 79.3 79.4 C-6"" 62.0 62.2 62.2 62.2 62.2 62.2 62.2 2'-O-Glu. C-1""' 103.6 103.6 103.6 103.7 C-2""' 76.3 76.4 76.1 76.4 C-3""' 78.1 78.2 78.3 78.2 C-4""' 72.4 72.3 72.4 72.5 C-5""' 77.8 78.0 78.4 77.8C-6""' 63.2 63.1 63.1 63.3 *(68MHz,ピリジン−d5,δc)TABLE 2 beta Bull astragaloside I (1), II (2 ), III (3), IV (4) and V (5) and related compounds (1a, 3a, 5a, 5b , 6) * for 13 C NMR data 1 1a 2 3 3a 4 5 5a 5b 6 C-1 38.4 38.5 38.5 38.6 38.6 38.6 38.6 38.6 38.6 38.5 C-2 26.4 26.5 26.5 26.6 26.6 26.6 26.4 26.5 26.5 26.5 C-3 89.2 89.4 89.3 89.2 89.2 89.2 89.5 89.5 89.6 89.3 C-4 39.3 39.5 39.5 39.5 39.5 39.5 39.5 39.5 39.5 39.5 C-5 55.5 55.6 55.7 55.7 55.7 55.7 55.8 55.8 55.6 55.7 C-6 18.3 18.5 18.4 18.5 18.5 18.4 18.5 18.5 18.5 18.4 C-7 33.0 33.0 33.3 33.1 33.1 33.1 33.1 33.1 33.2 33.3 C-8 39.7 39.9 39.7 39.9 39.9 39.7 39.9 39.9 39.9 39.7 C-9 47.8 47.9 47.9 48.0 48.0 48.0 48.0 48.0 48.0 47.9 C-10 36.7 36.9 36.9 36.9 36.9 36.9 36.9 36.9 36.9 36.9 C-11 23.2 23.4 23.8 23.4 23.4 23.4 23.4 23.4 23.2 23.8 C-12 122.7 122.9 122.5 122.8 122.8 122.5 122.8 122.8 122.9 122.5 C-13 144.0 144.1 144.8 144.1 144.1 144.8 144.1 144.1 144.2 144.8 C-14 42.0 42.1 42.1 42.1 42 .1 42.2 42.1 42.1 42.2 42.1 C-15 28.1 28.2 28.3 28.2 28.2 28.3 28.2 28.2 28.3 28.3 C-16 23.6 23.7 23.8 23.7 23.7 23.8 23.6 23.7 23.7 23.8 C-17 46.8 47.0 46.6 47.0 47.0 46.7 47.0 47.0 47.0 46.6 C-18 41.6 41.8 42.0 41.7 41.7 42.0 41.7 41.7 41.8 42.0 C-19 46.0 46.0 46.4 46.4 46.2 46.4 46.2 46.1 46.0 46.4 C-20 30.6 30.8 31.0 30.7 30.8 31.0 30.7 30.8 30.8 31.0 C-21 33.8 34.0 34.2 34.0 34.0 34.2 34.0 34.0 34.0 34.2 C- 22 32.4 32.5 33.2 32.5 32.5 32.1 32.5 32.5 32.6 33.2 C-23 27.9 28.0 28.1 28.1 28.1 28.2 28.0 28.0 28.0 28.1 C-24 16.7 16.9 16.9 16.9 16.9 16.9 16.7 16.7 16.8 16.9 C-25 15.3 15.5 15.4 15.5 15.5 15.4 15.5 15.5 15.5 15.4 C-26 17.3 17.4 17.3 17.4 17.4 17.4 17.4 17.4 17.6 17.3 C-27 26.0 26.1 26.2 26.1 26.1 26.2 26.1 26.1 26.1 26.2 C-28 176.3 176.4 180.1 176.4 176.4 180.2 176.4 176.4 176.4 180.1 C-29 33.0 33.0 33.3 32.1 33.1 33.1 33.1 33.1 33.2 33.3 C-30 23.5 23.6 23.8 23.6 23.6 23.8 23.4 23.6 23.4 23.8 3-O-Gluc.A C-1 '107.4 107.6 107.6 106.7 106.8 106.8 105.1 105.2 104.8 105.3 C-2' 7 1.9 72.0 72.1 74.8 74.7 74.8 78.3 78.2 79.1 78.3 C-3 '72.4 72.5 72.5 85.4 85.1 85.5 83.9 82.9 84.0 83.9 C-4' 70.0 70.1 70.1 72.3 72.3 72.4 72.9 73.2 71.1 72.9 C-5 '75.1 75.3 75.3 77.5 77.5 77.6 77.2 77.2 76.5 77.3 C-6 '171.4 171.4 171.6 172.4 172.4 172.4 172.2 172.3 170.3 172.2 6'-OMe 51.9 C-1 "171.0 171.1 171.2 174.8 174.6 174.6 174.5 177.4 170.3 174.5 1" -OMe 52.1 C-2 "93.8 93.8 94.0 74.2 74.2 74.2 73.0 72.6 82.8 72.8 2 "-OMe 58.9 C-3" 97.9 98.2 98.1 105.4 104.9 105.4 105.2 104.6 102.3 105.2 C-1 "'172.2 170.0 172.3 173.9 171.3 173.9 173.7 171.0 170.3 173.7 1"'-OMe 51.5 51.3 51.2 51.4 C-2 "'64.7 64.5 64.9 65.1 64.2 64.3 65.7 64.8 64.1 65.7 28-O-Glu. C-1""95.7 95.7 95.7 95.7 95.7 95.7 95.8 C-2""74.0 74.1 74.1 74.1 74.1 74.1 74.2 C-3""78.7 78.9 78.8 78.9 78.8 78.9 79.0 C-4 "" 70.9 71.1 71.1 71.1 71.1 71.1 71.1 C-5 "" 79.1 79.3 79.3 79.3 79.2 79.3 79.4 C-6 "" 62.0 62.2 62.2 62.2 62.2 62.2 62.2 2'-O-Glu. C-1 ""'103.6 103.6 103.6 103.7 C-2 ""' 76.3 76.4 76.1 76.4 C-3 ""'78.1 78.2 78.3 78.2 C- 4 ""'72.4 72.3 72.4 72.5 C-5 ""' 77.8 78.0 78.4 77.8 C-6 "" '63.2 63.1 63.1 63.3 * (68MHz, pyridine-d 5 , δc)

【0033】実施例2 テンサイ抽出軟エキスの調製 テンサイ根抽出工程 原料のテンサイ根12kgを秤量し、50%エタノール
10lを加え、90℃にて3時間加熱抽出し、冷却後、
150メッシュのふるいを通した後、濾紙(東洋濾紙N
o.2)を用いて濾紙し固液分離し、加熱抽出液(A)
を得る。濾取した加熱抽出残渣に50%エタノール10
lを加え、同じ操作を2回行い、加熱抽出液(B)、
(C)を得る。濾取した残渣は廃棄する。上記の加熱抽
出液(A)および(B)、(C)を約60℃にて減圧下
濃縮し、濃縮液(約4.5kg)を得る。この濃縮液を
90℃にて1時間加熱滅菌した後、滅菌精製水を用いて
テンサイ抽出軟エキスとしての製品規格であるブリック
ス40.0に調整する。テンサイ抽出軟エキスとしての
製品約5.0kgを得た。
Example 2 Preparation of soft extract of sugar beet Extracting step of sugar beet root 12 kg of sugar beet root as a raw material was weighed, 10 l of 50% ethanol was added, and heat extraction was performed at 90 ° C. for 3 hours, and after cooling,
After passing through a 150 mesh sieve, filter paper (Toyo Filter Paper N
o.2) for filter paper separation and solid-liquid separation, and heated extract (A)
Get. 50% ethanol was added to the heat extraction residue collected by filtration.
1 was added, the same operation was performed twice, and the heated extract (B),
(C) is obtained. Discard the residue collected by filtration. The heated extracts (A), (B), and (C) are concentrated under reduced pressure at about 60 ° C. to obtain a concentrated liquid (about 4.5 kg). The concentrated solution is sterilized by heating at 90 ° C. for 1 hour, and then sterilized purified water is used to adjust the product to Brix 40.0, which is the product standard as a soft extract of sugar beet. About 5.0 kg of the product as a sugar beet extract soft extract was obtained.

【0034】実施例3 テンサイ抽出乾燥エキス(粉末)の製造 テンサイ抽出軟エキス5.0kgのブリックスを滅菌精
製水を用いてブリックス50に調整し、90℃で30分
滅菌する。これを憤霧乾燥させて、テンサイ抽出乾燥エ
キス2.0kgを得る。
Example 3 Production of dried extract of sugar beet (powder) Brix of 5.0 kg of soft extract of sugar beet was adjusted to Brix 50 with sterile purified water and sterilized at 90 ° C. for 30 minutes. This is fog-dried to obtain 2.0 kg of dried extract of sugar beet.

【0035】実施例4 テンサイ抽出エキス細粒の製造 乳糖30kgを秤量し、フローコーターに入れ1分間造
粒し、これを予めデンプン1kgおよびテンサイ抽出軟
エキス10kgを加えて混合しておいたものを添加しな
がら、フローコーターで60分間憤霧造粒し、さらにフ
ローコーター中で10分間乾燥する。40〜80メッシ
ュのふるいを用いて整粒し、テンサイ抽出エキス細粒を
得た。
Example 4 Production of sugar beet extract fine granules 30 kg of lactose was weighed, put in a flow coater and granulated for 1 minute, and 1 kg of starch and 10 kg of sugar beet extract soft extract were added and mixed in advance. While adding, atomize and granulate for 60 minutes with a flow coater and further dry for 10 minutes in a flow coater. The particles were sized using a 40-80 mesh sieve to obtain sugar beet extract fine particles.

【0036】実施例5 テンサイ抽出エキス入り顆粒の製造 テンサイ乾燥エキス10kg、乳糖64.38kg、乾
燥デンプン7.37kg、ツェインDP(商品名)(ト
ウモロコシタンパク)0.8kgを混合機で約20分間
混合する。これにさらに無水エタノール22kgを添加
しハイスピードミキサーで約10分間練り合わせる。円
筒造粒機に移し、30回転/分にて造粒し、棚式乾燥機
で5時間乾燥する。16メッシュのふるいを用いて整粒
する。
Example 5 Production of Granules Containing Sugar Beet Extract Extract 10 kg of dried sugar beet extract, 64.38 kg of lactose, 7.37 kg of dried starch, 0.8 kg of Zein DP (trade name) (corn protein) were mixed in a mixer for about 20 minutes. To do. 22 kg of anhydrous ethanol was further added to this, and the mixture was kneaded with a high speed mixer for about 10 minutes. Transfer to a cylindrical granulator, granulate at 30 rpm, and dry for 5 hours in a tray dryer. The particles are sized using a 16 mesh sieve.

【0037】実施例6 テンサイ抽出エキス入り錠剤の製造 実施例5で得られた顆粒約80kgに滑沢剤としてしょ
糖脂肪酸エステル3kgを加え、混合機で15分間混合
した後、回転式(湿式)の打錠機で1錠約400mgの
錠剤に打錠した。
Example 6 Production of Tablets Containing Sugar Beet Extract Extract To about 80 kg of the granules obtained in Example 5, 3 kg of sucrose fatty acid ester was added as a lubricant, and the mixture was mixed for 15 minutes with a mixer, and then a rotary type (wet type) was used. Each tablet was compressed into tablets of about 400 mg with a tableting machine.

【0038】実施例7 テンサイ抽出エキス入りドリンクの製造 300リットルの精製水を70℃に加熱する。これにテ
ンサイ抽出軟エキス3kgおよび最終製品用の他のエキ
ス類少量を加えて撹拌および混合し、さらに少量のビタ
ミン類および酸類を加えて、再度撹拌および混合する。
これに糖類約300kgおよび1500リットル精製水
を加えて撹拌および溶解する。1μのフィルターで濾過
し、さらに適量の精製水を加えて、最終製品約3000
lに液量調整し、少量の香料を加えて撹拌する。中間タ
ンクでブリックスおよび酸度調整し、85℃に達するま
で加温し、80℃にて充填し缶またはびん入り製品とす
る。
Example 7 Preparation of drink containing sugar beet extract Extract 300 liters of purified water is heated to 70 ° C. To this, 3 kg of sugar beet extracted soft extract and a small amount of other extracts for the final product are added and stirred and mixed, and further a small amount of vitamins and acids are added and stirred and mixed again.
About 300 kg of saccharides and 1500 liters of purified water are added to this and stirred and dissolved. Filter through a 1μ filter and add an appropriate amount of purified water to obtain the final product of about 3000
Adjust the liquid volume to 1 and add a small amount of fragrance and stir. Adjust the brix and acidity in the intermediate tank, heat until reaching 85 ° C, and fill at 80 ° C to make a product in cans or bottles.

【0039】実施例8 テンサイエキス入り飴(キャンディー)の製造 水飴77.48kg、グラニュー糖66.71kg、テン
サイ抽出軟エキス0.94kgおよび黒糖14.84k
gを配合加熱器を用いて102〜109℃にて溶解す
る。60℃にて30分間撹拌し、バキュームクッカーで
水分が2%になるまで濃縮する。これに少量の香料を加
えて取りナベ中で混合し、冷却機を用いて冷却後混和す
る。バッチロールおよびサイジングローラーで圧延し、
スタンピングマシンを用いて成型して冷却コンベヤーで
室温まで冷却する。金属探知機にかけた後、目視検査す
る。これに、グラニュー糖22.2kg、色素少量、ア
ラビアゴム0.18kgおよびその他のものを加えてシ
ロップ調整して糖衣する。室温で1時間放置して乾燥さ
せて艶出しさせ、室温で一夜放置して乾燥させて目視検
査する。テンサイ抽出軟エキス入り飴(キャンデー)約
160kgを得た。
Example 8 Production of candy containing sugar beet extract (candy) 77.48 kg of starch syrup, 66.71 kg of granulated sugar, 0.94 kg of soft sugar beet extract and 14.84 k of brown sugar
g is melted at 102-109 ° C. using a compounding heater. Stir at 60 ° C. for 30 minutes and concentrate with a vacuum cooker until the water content is 2%. A small amount of fragrance is added to this, mixed in a pan, cooled using a cooler, and mixed. Roll with batch rolls and sizing rollers,
Mold using a stamping machine and cool to room temperature on a cooling conveyor. Visual inspection after metal detector. To this, 22.2 kg of granulated sugar, a small amount of pigment, 0.18 kg of gum arabic and others are added, and a syrup is adjusted to apply sugar. Let stand at room temperature for 1 hour to dry and polish, then let stand at room temperature overnight to dry and inspect visually. About 160 kg of candy (candy) containing sugar beet extracted soft extract was obtained.

【0040】実施例9 テンサイエキス入りクッキーの製造 三温糖20kgおよびショートニング10kgを秤量し
て撹拌および混合する。これにテンサイ軟エキス1kg
および甘味料0.2kgおよび適量の香料などの液体原
料類を加え、撹拌および混合し、大豆タンパク16k
g、大豆繊維4kgなどのその他の原料類20kgを加
え、再度撹拌および混合する。これに卵20kgおよび
小麦粉30kgを加えて練り合わせて生地を作成する。
生地を厚さ4mmのローラーに成型器で型を抜く。型抜
きしたものをバンドオーブンに入れて、180℃で15
分間焼き上げる。冷却後約100kgのテンサイ抽出軟
エキス入りクッキー100kgを得た。
Example 9 Preparation of cookie containing sugar beet extract 20 kg of trio sugar and 10 kg of shortening are weighed, stirred and mixed. 1kg of sugar beet soft extract
And 0.2 kg of sweetener and liquid raw materials such as a proper amount of flavor and the like, stirred and mixed, soybean protein 16k
20 kg of other raw materials such as g and 4 kg of soybean fiber are added, and the mixture is stirred and mixed again. 20 kg of eggs and 30 kg of flour are added to this and kneaded to prepare a dough.
Die the dough on a roller with a thickness of 4 mm with a molding machine. Put the die-cut into a band oven and leave it at 180 ° C for 15
Bake for minutes. After cooling, about 100 kg of sugar beet extracted soft extract-containing cookies 100 kg were obtained.

【0041】実施例10 テンサイ抽出軟エキス含有チュウインガムの製造 ガムベース60kg、砂糖168kg、水飴39kg、
ブドウ糖30kg、軟化剤3kgに、あらかじめテンサ
イ抽出軟エキスを2倍量の水で希釈して得られたテンサ
イ抽出軟エキス水溶液3kgを添加して、常法に従って
テンサイ抽出エキスを含有するチュウインガムを作製し
た。
Example 10 Production of chewing gum containing soft beet extract: 60 kg of gum base, 168 kg of sugar, 39 kg of starch syrup,
To 30 kg of glucose and 3 kg of a softening agent, 3 kg of a sugar beet extract soft extract aqueous solution obtained by previously diluting a sugar beet extract soft extract with twice the amount of water was added to prepare a chewing gum containing the sugar beet extract according to a conventional method. .

Claims (7)

【特許請求の範囲】[Claims] 【請求項1】 式A: 【化1】 [式中、R1は、Hまたはβ−D−Gluであり、 R3およびR4は、HまたはCH3である]で示される化
合物、または式B: 【化2】 [式中、R1、R3およびR4は前記と同じ意味であり、 R2は、Hまたはβ−D−Gluである]で示される化合
物。
1. Formula A: ## STR1 ## [Wherein R 1 is H or β-D-Glu, and R 3 and R 4 are H or CH 3 ], or a compound of the formula B: [Wherein R 1 , R 3 and R 4 have the same meanings as described above, and R 2 is H or β-D-Glu].
【請求項2】 請求項1に記載の化合物の少なくとも1
種を含むテンサイの抽出エキス。
2. At least one of the compounds according to claim 1.
Extract of sugar beet including seeds.
【請求項3】 請求項1に記載の化合物の少なくとも1
種を有効成分として含む血糖降下活性医薬組成物。
3. At least one of the compounds according to claim 1.
A hypoglycemic active pharmaceutical composition comprising a seed as an active ingredient.
【請求項4】 請求項2に記載の抽出エキスを有効成分
として含む血糖降下活性医薬組成物。
4. A hypoglycemic active pharmaceutical composition containing the extract according to claim 2 as an active ingredient.
【請求項5】 式A: 【化3】 [式中、R1は、Hまたはβ−D−Gluであり、 R3およびR4は、Hまたは低級アルキルである]で示さ
れる化合物、および式B: 【化4】 [式中、R1、R3およびR4は前記と同じ意味であり、 R2は、Hまたはβ−D−Gluである]で示される化合物
の少なくとも1種を有効成分として含む血糖降下活性医
薬組成物。
5. Formula A: [Wherein R 1 is H or β-D-Glu, and R 3 and R 4 are H or lower alkyl], and a compound of the formula B: [In the formula, R 1 , R 3 and R 4 have the same meaning as described above, and R 2 is H or β-D-Glu] A hypoglycemic activity containing at least one compound represented by the formula Pharmaceutical composition.
【請求項6】 請求項1に記載の化合物の少なくとも1
種を有効成分として含む機能性食品。
6. At least one of the compounds according to claim 1.
Functional food containing seed as an active ingredient.
【請求項7】 請求項2に記載の抽出エキスを有効成分
として含む機能性食品。
7. A functional food containing the extract according to claim 2 as an active ingredient.
JP7177220A 1995-07-13 1995-07-13 New compound included in sugar beet, medical composition and function food Pending JPH0925290A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP7177220A JPH0925290A (en) 1995-07-13 1995-07-13 New compound included in sugar beet, medical composition and function food

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7177220A JPH0925290A (en) 1995-07-13 1995-07-13 New compound included in sugar beet, medical composition and function food

Publications (1)

Publication Number Publication Date
JPH0925290A true JPH0925290A (en) 1997-01-28

Family

ID=16027264

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7177220A Pending JPH0925290A (en) 1995-07-13 1995-07-13 New compound included in sugar beet, medical composition and function food

Country Status (1)

Country Link
JP (1) JPH0925290A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005053860A (en) * 2003-08-06 2005-03-03 Yoshimitsu Ida Triterpene derivative
JP2013035794A (en) * 2011-08-09 2013-02-21 Nippon Beet Sugar Mfg Co Ltd Rxr and/or ppar activator
US8697145B2 (en) 2005-06-03 2014-04-15 Horizon Science Pty. Ltd. Substances having body mass redistribution properties
US9161562B2 (en) 2004-06-04 2015-10-20 Horizon Science Pty Ltd Natural sweetener
US9364016B2 (en) 2006-09-19 2016-06-14 The Product Makers (Australia) Pty Ltd Extracts derived from sugar cane and a process for their manufacture
US9572852B2 (en) 2011-02-08 2017-02-21 The Product Makers (Australia) Pty Ltd Sugar extracts
US10350259B2 (en) 2013-08-16 2019-07-16 The Product Makers (Australia) Pty Ltd Sugar cane derived extracts and methods of treatment
US11730178B2 (en) 2012-08-28 2023-08-22 Poly Gain Pte Ltd Extraction method

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005053860A (en) * 2003-08-06 2005-03-03 Yoshimitsu Ida Triterpene derivative
US9161562B2 (en) 2004-06-04 2015-10-20 Horizon Science Pty Ltd Natural sweetener
US8697145B2 (en) 2005-06-03 2014-04-15 Horizon Science Pty. Ltd. Substances having body mass redistribution properties
US9364016B2 (en) 2006-09-19 2016-06-14 The Product Makers (Australia) Pty Ltd Extracts derived from sugar cane and a process for their manufacture
US9572852B2 (en) 2011-02-08 2017-02-21 The Product Makers (Australia) Pty Ltd Sugar extracts
US9717771B2 (en) 2011-02-08 2017-08-01 The Product Makers (Australia) Pty Ltd Sugar extract
US10226502B2 (en) 2011-02-08 2019-03-12 The Product Makers (Australia) Pty Ltd Sugar extract
JP2013035794A (en) * 2011-08-09 2013-02-21 Nippon Beet Sugar Mfg Co Ltd Rxr and/or ppar activator
US11730178B2 (en) 2012-08-28 2023-08-22 Poly Gain Pte Ltd Extraction method
US10350259B2 (en) 2013-08-16 2019-07-16 The Product Makers (Australia) Pty Ltd Sugar cane derived extracts and methods of treatment

Similar Documents

Publication Publication Date Title
EP1213020B1 (en) Compounds and pharmaceutical compositions having appetite suppressant activity
JP6014640B2 (en) Rebaudioside A derivative product and production method
YOSHIKAWA et al. Medicinal foodstuffs. III. Sugar beet.(1): Hypoglycemic oleanolic acid oligoglycosides, betavulgarosides, I, II, III, and IV, from the root of Beta vulgaris L.(Chenopodiaceae)
Ma et al. Additional toxic, bitter saponins from the seeds of Chenopodium quinoa
US6376682B1 (en) Compound with α-glucosidase inhibiting action and method for producing the same
MX2011010858A (en) Compounds affecting glycemic index.
JPH0925290A (en) New compound included in sugar beet, medical composition and function food
CN112569136A (en) Composition for improving skin elasticity comprising novel ginsenoside
CN106715452B (en) Compound KS513, compositions containing same and uses thereof
JP4833854B2 (en) Composition comprising an alcohol compound having anti-adipogenic and anti-obesity activity isolated from an extract of Cucurbitaceae
JPH0899993A (en) Production of saponins of aralia elata seem., method for isolating the same and use
JPH09124682A (en) Unknown compound occurring in beet and functional food product containing the same
JPS6230711A (en) Drug for alleviating hypercholesterolemia
JP5186084B2 (en) Robofruit-containing saponin and its use
KR101338172B1 (en) Pharmaceutical composition comprising the extract paeonia lactiflora, fraction thereof or compound isolated therefrom as an active ingredient
WO2013111924A1 (en) Novel compound derived from ishige foliacea, and use thereof
US6833443B1 (en) Gymnemic acid derivatives, process for the preparation thereof and use thereof as medicine
CN110882244B (en) Use of terpene lactones for ameliorating gastric motility disorders
KR102271457B1 (en) Composition for Preventing or Treating Xerostomia Comprising Ixeridium dentatum Aerial Part Extract or Compounds Isolated therefrom
KR100748364B1 (en) Composition comprising 3-o-methylursolic acid isolated from euonymus alatus for the prevention and treatment of diabetes mellitus
KR101991899B1 (en) Composition for preventing or treating diabetes comprising goyaglycoside G isolated from Mormodica charantia extract as an active ingredient
CN109232701B (en) Antitumor active monomer of sweet potato, antitumor extract of sweet potato, preparation method and application thereof
EP0636633A1 (en) A triterpenoid saponin, extraction thereof and use to treat or prevent diabetes mellitus
AU780886B2 (en) Appetite suppresant steroidal glycosides
WO2003073870A1 (en) Health foods having antiallergic effect

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20041220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051004

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060214